ArticleFrontiers in immunology2026
Circulating antibody signatures against
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tuberculosis (TB), caused by Methods: In this work, we analyzed a large cohort of patients with active TB by integrating clinical, radiological, and laboratory variables. Using Factor Analysis of Mixed Data (FAMD) to define a range of severity-associated phenotypes, two principal components of variation, related to systemic and pulmonary severity were identified and combined in an overall score. Plasma circulating IgG responses against ESAT-6/CFP-10, Ag85A, HspX and Rv2626c -four key antigens with distinct behaviors during metabolic switches of Results: Individual antibody responses showed limited associations with severity. However, specific antibody signatures presented a significantly higher effect. A signature defined by IgG responses against ESAT-6/CFP-10, Ag85A, and HspX (excluding Rv2626c) was associated with higher severity scores and features of advanced pulmonary disease. In contrast, signatures containing antibodies against Rv2626c were mainly associated with milder phenotypes. Conclusion: These findings demonstrate that antigen-specific IgG signatures show significant associations with specific forms of TB pathology. Additional prospective and longitudinal studies will be required to study their potential as biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.